CryoLife, Inc. (NYSE:CRY) – Investment analysts at First Analysis lowered their FY2017 EPS estimates for shares of CryoLife in a research note issued on Tuesday. First Analysis analyst now expects that the medical equipment provider will post earnings of $0.27 per share for the year, down from their prior forecast of $0.29. First Analysis also issued estimates for CryoLife’s Q4 2017 earnings at $0.08 EPS, Q1 2018 earnings at $0.01 EPS, Q2 2018 earnings at $0.06 EPS and FY2018 earnings at $0.15 EPS.
A number of other brokerages also recently commented on CRY. Canaccord Genuity restated a “buy” rating and issued a $25.00 target price on shares of CryoLife in a research note on Monday, October 9th. Lake Street Capital upped their target price on shares of CryoLife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research downgraded shares of CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. BidaskClub downgraded shares of CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, TheStreet downgraded shares of CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. CryoLife currently has a consensus rating of “Hold” and an average target price of $23.63.
COPYRIGHT VIOLATION WARNING: “FY2017 EPS Estimates for CryoLife, Inc. (CRY) Lowered by First Analysis” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/15/fy2017-eps-estimates-for-cryolife-inc-cry-lowered-by-first-analysis.html.
Shares of CryoLife (CRY) opened at $19.35 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90. CryoLife has a 1 year low of $14.02 and a 1 year high of $24.00. The firm has a market cap of $637.37, a PE ratio of 46.46 and a beta of 0.82.
CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.08. CryoLife had a net margin of 5.28% and a return on equity of 6.43%. The company had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same period in the prior year, the company posted $0.13 EPS. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its stake in shares of CryoLife by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,994,820 shares of the medical equipment provider’s stock valued at $45,282,000 after purchasing an additional 34,599 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of CryoLife by 6.6% during the second quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock valued at $33,090,000 after purchasing an additional 102,540 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of CryoLife by 16.0% during the third quarter. Macquarie Group Ltd. now owns 1,609,284 shares of the medical equipment provider’s stock valued at $36,531,000 after purchasing an additional 221,574 shares in the last quarter. Northern Trust Corp boosted its stake in shares of CryoLife by 7.4% during the second quarter. Northern Trust Corp now owns 1,171,769 shares of the medical equipment provider’s stock valued at $23,377,000 after purchasing an additional 81,090 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of CryoLife by 5.2% during the second quarter. State Street Corp now owns 758,840 shares of the medical equipment provider’s stock valued at $15,143,000 after purchasing an additional 37,279 shares in the last quarter. Hedge funds and other institutional investors own 70.34% of the company’s stock.
In other CryoLife news, Director James Benson sold 2,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $22.80, for a total value of $45,600.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO David Ashley Lee sold 33,190 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total transaction of $630,610.00. Following the completion of the transaction, the chief financial officer now owns 324,339 shares in the company, valued at $6,162,441. The disclosure for this sale can be found here. Insiders sold a total of 209,240 shares of company stock worth $4,495,465 over the last 90 days. Insiders own 6.00% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.